Priya Jayachandran
Overview
Explore the profile of Priya Jayachandran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
593
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nasca V, Zhao J, Ros J, Lonardi S, Zwart K, Cohen R, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39929672
Background: Immune checkpoint inhibitors (ICIs) are the gold standard therapy in patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). A significant proportion of patients show resistance,...
2.
Taieb J, Ambrosini M, Alouani E, Lonardi S, Sinicrope F, Decraecker M, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39755579
Background: Immune checkpoint inhibitors (ICIs) are recommended to treat patients with deficient mismatch repair/microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC). Pivotal trials have fixed a maximum ICI duration of...
3.
Mittal P, Battaglin F, Baca Y, Xiu J, Farrell A, Soni S, et al.
Int J Cancer
. 2024 Dec;
156(8):1583-1593.
PMID: 39740007
Myeloid cell leukemia 1 (MCL-1) is a member of the B-cell lymphoma 2 protein family and has anti-apoptotic functions. Deregulation of MCL-1 has been reported in several cancers, including lung...
4.
Jayachandran P, Knochel J, Cicali B, Rowland Yeo K
CPT Pharmacometrics Syst Pharmacol
. 2024 Nov;
13(11):1815-1819.
PMID: 39552441
No abstract available.
5.
Arai H, Gandhi N, Battaglin F, Wang J, Algaze S, Jayachandran P, et al.
J Immunother Cancer
. 2024 Nov;
12(11.
PMID: 39500526
Background: In patients with colorectal cancer (CRC), the therapeutic effects of conventional immune checkpoint inhibitors targeting the adaptive immune system are largely limited to those with microsatellite instability-high tumors. Meanwhile,...
6.
Venkatakrishnan K, Jayachandran P, Seo S, van der Graaf P, Wagner J, Gupta N
Clin Transl Sci
. 2024 Jun;
17(6):e13859.
PMID: 38923292
No abstract available.
7.
Venkatakrishnan K, Jayachandran P, Seo S, van der Graaf P, Wagner J, Gupta N
CPT Pharmacometrics Syst Pharmacol
. 2024 May;
13(6):909-918.
PMID: 38778466
No abstract available.
8.
Pan Y, Chiu T, Zhou L, Chan P, Kuo T, Battaglin F, et al.
bioRxiv
. 2024 May;
PMID: 38746115
Circadian clock genes are emerging targets in many types of cancer, but their mechanistic contributions to tumor progression are still largely unknown. This makes it challenging to stratify patient populations...
9.
Venkatakrishnan K, Jayachandran P, Seo S, van der Graaf P, Wagner J, Gupta N
Clin Pharmacol Ther
. 2024 May;
115(6):1187-1197.
PMID: 38736240
No abstract available.
10.
Arai H, Yang Y, Baca Y, Millstein J, Denda T, Ou F, et al.
Eur J Cancer
. 2024 Feb;
201:113914.
PMID: 38359495
Background: CDC37 is a key determinant of client kinase recruitment to the HSP90 chaperoning system. We hypothesized that kinase-specific dependency on CDC37 alters the efficacy of targeted therapies for metastatic...